These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19663522)

  • 1. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects.
    Darwish M; Kirby M; Hellriegel ET
    Clin Drug Investig; 2009; 29(9):601-12. PubMed ID: 19663522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.
    Darwish M; Kirby M; Hellriegel ET; Robertson P
    Clin Drug Investig; 2009; 29(9):613-23. PubMed ID: 19663523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.
    Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
    Drugs Aging; 2011 Feb; 28(2):139-50. PubMed ID: 21275439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.
    Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
    Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss.
    Dinges DF; Arora S; Darwish M; Niebler GE
    Curr Med Res Opin; 2006 Jan; 22(1):159-67. PubMed ID: 16393442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships.
    Darwish M; Bond M; Ezzet F
    J Clin Pharmacol; 2012 Sep; 52(9):1328-42. PubMed ID: 22039290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites.
    Willavize S; Fiedler-Kelly J; Ludwig E; Guan L
    J Clin Pharmacol; 2017 Feb; 57(2):255-265. PubMed ID: 27436172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder.
    Rosenberg RP; Bogan RK; Tiller JM; Yang R; Youakim JM; Earl CQ; Roth T
    Mayo Clin Proc; 2010 Jul; 85(7):630-8. PubMed ID: 20530317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
    Wong YN; Simcoe D; Hartman LN; Laughton WB; King SP; McCormick GC; Grebow PE
    J Clin Pharmacol; 1999 Jan; 39(1):30-40. PubMed ID: 9987698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
    Biederman J; Swanson JM; Wigal SB; Boellner SW; Earl CQ; Lopez FA;
    J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects.
    Xu P; Li HD; Zhang BK; Xiao YW; Yuan HY; Zhu YG
    J Clin Pharm Ther; 2008 Aug; 33(4):429-37. PubMed ID: 18613861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Drug Investig; 2014 Oct; 34(10):691-9. PubMed ID: 25047407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.
    Lower EE; Malhotra A; Surdulescu V; Baughman RP
    J Pain Symptom Manage; 2013 Feb; 45(2):159-69. PubMed ID: 22917711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C.
    Rabkin JG; McElhiney MC; Rabkin R
    Int J STD AIDS; 2011 Feb; 22(2):95-101. PubMed ID: 21427431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of modafinil and its acid and sulfone metabolites in Chinese males.
    Seng KY; Fan L; Lee HS; Yong WP; Goh BC; Lee LS
    Ther Drug Monit; 2011 Dec; 33(6):719-29. PubMed ID: 22105589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Armodafinil for excessive daytime sleepiness.
    Nishino S; Okuro M
    Drugs Today (Barc); 2008 Jun; 44(6):395-414. PubMed ID: 18596995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single dose of armodafinil significantly promotes vigilance 11 hours post-dose.
    Phillips JB; Simmons RG; Arnold RD
    Mil Med; 2011 Jul; 176(7):833-9. PubMed ID: 22128728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.